ISTR 2023 – International Symposium on Trends in Radiopharmaceuticals

Background

Advances in nuclear medicine have opened possibilities to generate unprecedented solutions to clinical problems by providing better diagnosis and more efficient therapies. Emerging new radiopharmaceuticals and efficient production of relevant radioisotopes have been always tightly linked to these developments.

Impressive technologies including high-energy and high-current accelerators are now becoming available for radioisotope production in addition to the existing ones. This has allowed broader access to several promising radionuclides, including gallium-68, copper-64 and zirconium-89. Development of high-power electron linacs resulted in the production of therapeutic radionuclides such as scandium-47, actinium-225, and copper-67. Alternative methods, using both electron and proton accelerators, are being developed for large scale production of molybdenum-99/technetium-99m, which remains the most widely used diagnostic radionuclide.

Purpose and Objectives

The International Symposium on Trends in Radiopharmaceuticals, ISTR-2023, will provide scientists and other professionals working in the production of radioisotopes and radiopharmaceuticals with an international forum to discuss the most recent developments and challenges in the field. Topics covered during the event, including the development, production and uses of diagnostic, therapeutic and theranostic radioisotopes and radiopharmaceuticals, as well as regulatory and licensing issues. Education, certification and training methodologies will also be addressed. We expect participants from academia, industry, healthcare institutions, regulatory bodies and other organizations. Read more →

Target Audience

The target audience for this Symposium includes (radio)chemists, (radio)pharmacists, biologists, physicists, technologists, medical researchers, policy makers and health regulators, educators and other professionals working in the fields of production and uses of medical radioisotopes and radiopharmaceuticals. The IAEA welcomes and encourages the participation of individuals from developing countries, women, and early career professionals including students.